Kornimate/medical-research-clean huggingface dataset:
the correlation between cited2 and collateral circulation in acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: evaluating the collateral circulation of acute ischemic stroke (ais) mainly depends on the imaging examination. at present, there is no effective and sensitive biomarker for collateral circulation. thus, the research objective was to evaluate the predicting role of the cbp/p300-interacting transactivator with glu/asp-rich c-terminal domain 2 ratio (cited2) from peripheral blood mononuclear cells in the collateral circulation of ais. we classified the ais patients into two groups (the good collateral group and the poor collateral group) by dwi-aspects score. the western blot was applied to test the protein expression of vascular endothelial growth factor (vegf) and cited2. then, we collected other clinical data. binary logistic regression analysis between collateral circulation and clinical data was performed. finally, receiver operating characteristic (roc) curve analysis was used to explore the predictive value of the cited2.


Eligibility criteria:
inclusion criteria: * the first-time onset or previous stroke with mrs score ≤1, and the onset time less than 3 days without intravenous thrombolysis or endovascular therapy ; * age range of 18 to 80 years old; * patients with a clinical diagnosis of acute ischemic stroke; ④ nihss score ≥4; ⑤ patients volunteer to participate in this study and signed a written informed consent exclusion criteria: * ①the patients with ais combined with other diseases that may affect the cited2 and vegf expression, such as acute myocardial infarction, peripheral artery occlusion disease and congenital heart defect; * the patients exhibited serious heart, live or kidney diseases; ③disturbance of consciousness or mental illness; ④ patients with tumor; ⑤ pregnant and lactating patients.
norplant and irregular bleeding/spotting

Conditions: Endometrial Bleeding; Periodontal Disease

Summary: irregular or prolonged menstrual bleeding and/or spotting are common side effects in patients using progestin-only hormonal contraception such as levonorgestrel implants (norplant). doxycycline, a drug approved by the food and drug administration (fda) to treat gum disease, may reduce the occurrence of uterine bleeding and spotting in women who use norplant. this study will evaluate the effects of doxycycline on uterine bleeding/spotting in women using norplant.

a high percentage of women using progestin-only contraception experience breakthrough bleeding (btb) and spotting that causes impaired lifestyle and results in decreased compliance with this contraceptive method. there is a need for an effective, low-cost, easily adapted treatment to reduce the bleeding and spotting in progestin-only contraceptives. the molecular environment of the endometrium of women with btb and spotting contains abnormally high levels of pro-inflammatory cytokines (tnf-alpha and il-1 beta) and abnormally high levels of proteases (matrix metalloproteinases \[mmps\] and neutrophil elastase), which prevent normal tissue repair. doxycycline (dox) is an inexpensive, fda approved antibiotic that inhibits mmps and reduces nitric oxide synthesis. this study will evaluate dox treatment of progestin-only contraceptive induced btb and spotting, characterize the endometrial molecular biologic changes that occur in dox treated patients, and determine the effect of norplant on sexual functioning and testosterone levels. all participants in this study will receive norplant. participants will then be randomized to receive either dox (20 mg twice a day) or placebo for 6 months. participants will have 9 study visits during the 24 weeks of the study. study visits will include a medical history, physical exam, and blood and urine tests. participants will also have three periodontal evaluations and three endometrial biopsies. at the end of the study, participants may choose to have the norplant implant removed if they wish to discontinue norplant use; otherwise the implant may remain in for up to 5 years.

Eligibility criteria:
inclusion criteria * regular menstrual periods for the last 2 cycles * currently not using hormonal contraceptives, including oral contraceptives, patch, ring, or norplant in 2 months prior to study entry, or depo-provera in 12 months prior to study entry * currently not using tetracycline-class antibiotics * normal pap smear exclusion criteria * pregnancy or breastfeeding within 2 months of study entry * chronic migraine headaches * uncontrolled high blood pressure * untreated sexually transmitted diseases * alcoholism or drug abuse within 12 months of study entry * insulin dependent diabetes * liver, kidney, or gallbladder disease * participation in another clinical trial within 30 days of study entry * history of cancer * history of blood clots, strokes, or heart disease

Keywords: norplant periodontal disease endometrial bleeding progestin-induced endometrial bleeding
low-dose enoxaparin in psoriasis

Conditions: Psoriasis

Summary: rationale: * psoriasis is a chronic immune-mediated inflammatory skin disorder where t cells play a fundamental role in its pathogenesis. * low molecular weight heparin has been reported to exert immunomodulatory effect at small doses through inhibition of t cells heparinase enzyme. * low molecular weight heparin may have promising results for treatment of psoriasis. research question: * can low molecular weight heparin be used safely for treatment of psoriasis with good outcome? * is enoxaparin inhibitory effect on t cell heparinase enzyme responsible for its beneficial effect? hypothesis: * low molecular weight heparin can achieve good results when used at small doses for treatment of psoriasis. * heparin can exert immunomodulatory effect in psoriasis through inhibition of t cell heparinase enzyme. aim of work -the aim of this work is to assess the possible clinical efficacy and safety of low-dose enoxaparin in the treatment of psoriasis and to detect if inhibition of heparinase enzyme might account for its beneficial therapeutic effect. objectives: * to evaluate safety and efficacy of low molecular weight heparin at small dose for treatment of psoriasis. * contribute to the ongoing efforts to optimize psoriasis management and improve the lives of individuals affected by this chronic condition.


Eligibility criteria:
inclusion criteria: * patients with plaque psoriasis, who met the following criteria will be enrolled. 1. age 18 and above. 2. no systemic (oral, parenteral, photobiological) treatment for psoriasis within the last 2 months. 3. no topical treatment for psoriasis within the last 2 weeks. exclusion criteria: * 1. pregnancy or lactation. 2. hypersensitivity to heparin and heparin derivatives and a history of heparin-induced thrombocytopenia. 3. history of bleeding diathesis, uncontrolled hypertension, cerebrovascular accident, peptic ulcer, liver disease and/or abnormal liver function tests or abnormal kidney function tests. 4. history of major surgery within the last 3 months. 5. a family history of bleeding diathesis, or cerebrovascular accident. 6. concomitant use of oral anticoagulants, acetylsalicylic acid, or other nonsteroidal anti-inflammatory drugs.
rtms effect in functional psychogenic movement disorders applied alone then combined with hypnotherapy

Conditions: Movement Disorders

Summary: the management of functional psychogenic movement disorders (fnpmd) is challenging for neurologists and psychiatrists and only comprehensive multidisciplinary treatment programme can be worthwhile for these patients (moene et al 2002). recent functional magnetic resonance imaging studies have demonstrated abnormalities in motor control at cortical level, hyperactivity of limbic system and disturbance of connectivity between these two systems leading to a lack of self-agency, (voon et al 2010,2011).two recent studies suggested a possible therapeutic effect of transcranial magnetic stimulation (tms) in fnpmd (dakotakis 2011, garcin, 2013). in this protocol our objectives are twofold : 1. to compare the effect of 5 consecutive daily sessions of rtms on fnpmd in a double-blind randomized controlled study 2. to study the effect of 3 weekly hypnosis sessions combined with rtms in fnpmd


Eligibility criteria:
inclusion criteria: * man or woman with fnpmd for at least 2 months, * diagnosed from clinical diagnostic and statistical manual v conversive somatoform troubles and gupta \& lang (2009) and edwards \& bahtia 2012 neurological clinical criteria exclusion criteria: * severe progressive psychiatric disorders * cardiac pace-maker * metallic prosthesis * cochlear implants * previous neurosurgery * epilepsy * severe cardiac disease * alcohol or toxic abuse for the last 12 months * drugs such clozapine, bupropion, methadone or theophylline
expanded access remdesivir (rdv; gs-5734™)

Conditions: Coronavirus Disease 2019

Summary: disease caused by 2019 novel coronavirus also known as severe acute respiratory syndrome coronavirus 2 (sars-cov-2)

the treatment of communicable novel coronavirus (codiv-19) of 2019 with remdesivir (rdv; gs-5734™) also known as severe acute respiratory syndrome coronavirus 2 (sars-cov-2)

Eligibility criteria:
inclusion criteria: * dod-affiliated personnel as defined in dodi 6200.02, which includes emergency-essential civilian employees and/or contractor personnel accompanying the armed forces who are subject to the same health risk as military personnel * have a laboratory-confirmed covid-19 diagnosis with moderate to severe disease presentation as determined by the principal investigator * patient or legally authorized representative (lar) provides written informed consent, except as noted in 21 cfr 50.23 * understands and agrees to comply with planned study procedures * available for clinical follow-up for duration of the treatment and follow-up period * woman of childbearing potential must * have a negative pregnancy test within 24 hours before starting treatment * agree not to become pregnant during treatment and for 1 months after receiving remdesivir (treatment will be a maximum of 10 doses given over a 10-day interval) * use at least 2 reliable forms of effective contraception, including 1 barrier method, during treatment and for 1 month after the treatment period exclusion criteria: * alt/ast ≥ 5 times the upper limit of normal * stage 4 severe kidney disease or requiring dialysis (i.e. egfr \<30) * anticipated transfer to another hospital that is not a study site within 72 hours * allergy to any components of the study medication \[gs-5734, sulfobutylether β-cyclodextrin sodium (sbecd) and hydrochloric acid and/or sodium hydroxide\] * concomitant antiviral therapy (lopinavir/ritonavir \[kaletra\]) * pregnant or nursing

Keywords: covid-19 gs-5734 remdesivir sars-cov-2
improving beliefs about medication in patients with rheumatoid arthritis

Conditions: Musculoskeletal Diseases; Rheumatoid Arthritis

Summary: the purpose of this study is to determine if a short motivational patient-centered intervention for non-adherent patients is more successful in improving beliefs about medication (and adherence) compared to a usual care control group of non-adherent patients.

disease modifying anti rheumatic drugs (dmards) reduce disease activity and radiological progression and improve long term functional outcome in patients with rheumatoid arthritis (ra). however, adherence is a prerequisite for a drug to be effective. a previous study showed that 33% of the ra-patients using dmards are non-adherent. non-adherence can not be attributed to a single cause, but is the result of a complex and individual decision process. an intervention should not only consider practical barriers, such as forgetfulness, but also cognitive and other psychological variables that might impact medication adherence. therefore, an intervention was developed focusing primarily on the non-adherent patient's individual beliefs and barriers to adherence. the effectiveness of this intervention will be evaluated in a randomized clinical trial. primary outcome measure is beliefs about medication assessed with the beliefs about medicines questionnaire (bmq). additionally, adherence and adherence-related variables will be measured with questionnaires.

Eligibility criteria:
inclusion criteria: * ra according to the 1986 acr criteria for at least 1 year * prescription of anti-rheumatic medication (dmards) * non-adherent patients (compliance questionnaire rheumatology) exclusion criteria: * co-morbidity (physical or psychological) that unables patient to participate in the intervention * illiteracy * inability to communicate in dutch * participation in other studies with significant burden

Keywords: adherence compliance rheumatoid arthritis intervention beliefs about medication motivational interviewing medication adherence patient compliance intervention studies
clobazam use in epilepsia partialis continua - pilot study

Conditions: Epilepsia Partialis Continua; Kojewnikov's Epilepsy; Epilepsy

Summary: the purpose of this study is to evaluate whether clobazam, brand name onf®, is more effective as an adjunctive or monotherapy in terminating epilepsia partialis continua (epc) than either lorazepam and/or clonazepam.

first approved in the united states in 2011 for use in treating lennox-gastaut syndrome, clobazam is the only 1, 5-benzodiazepine that is currently approved for clinical use in the united states. in previous clinical trials clobazam has been shown to have a greater efficacy and produce fewer side effects in individuals when it's adverse event profile is compared to the traditional 1,4-benzodiazepines such as diazepam, lorazepam, and clonazepam. as a benzodiazepine, clobazam has been found to have anticonvulsant properties, and structural differences as a 1,5-benzodiazepines that appear to have a broader spectrum of anticonvulsant activity than those found in 1,4-benzodiazepines. in previous reports, clobazam has been seen to be effective in ether terminating or reducing both epc in particular and partial status epilepticus.

Eligibility criteria:
inclusion criteria: •≥ to 18 yrs of age •diagnosis of epc by a neurologist exclusion criteria: * previous exposure to clobazam prior to presentation * seizure generalization * patients who are intubated and on iv sedation such as versed®, propofol or presedex®. * female subjects who are pregnant and/or breast-feeding * subject has an unstable and/or serious or psychiatric illness * subject has an unstable and/or serious medical illness * subject has any of the following but not limited to conditions: * a life threatening medical condition * severe sepsis or septic shock * severe renal impairment * severe hepatic impairment * sleep apnea * narrow angle glaucoma * severe respiratory insufficiency * myasthenia gravis * metastatic cancer * organ failure * severe progressive nervous system disease * a clinically significant ekg abnormality that would be affected by and/or affect the patient's participation in the trial * subject has active suicidal ideation at screening and baseline visits * subject has a history of suicidal thoughts or behaviors, which would be indicated by a positive response to questions 4 and/or 5 on the cssr-s. exclusionary actions include but are not limited to: * previous intent to act on suicidal ideation with a specific plan * previous preparatory acts or behavior * a previous actual attempt, interrupted attempt or aborted suicide attempt * subject has a history of alcohol and/or substance abuse in the previous 12 months, or the subject is unable to refrain from alcohol and/or substance abuse during the study. * subject admits to present illicit drug use or has a positive drug screen * subject is currently enrolled in or has been enrolled in any clinical trial within the past 30 days * subject has a known allergy to any component of the study medication(s)

Keywords: epilepsia partialis continua kojewnikov's epilepsy epilepsy clobazam focal motor epilepsy partial motor seizure
a study of the effect of vemurafenib on the pharmacokinetics of phenprocoumon in patients with brafv600 mutation-positive metastatic malignancy

Conditions: Malignant Melanoma, Neoplasms

Summary: this open-label, multicenter, parallel study will evaluate the effect of multiple doses of vemurafenib on the pharmacokinetics of a single dose of phenprocoumon in patients with brafv600 mutation-positive metastatic malignancies. patients will be randomized to receive either treatment a: a single oral dose of phenprocoumon 6 mg on day 1 (eligible patients will have the option to continue treatment with vemurafenib as part of an extension study (nct01739764).), or treatment b: vemurafenib 960 mg orally twice daily on days 1-29 plus a single oral dose of phenprocoumon 6 mg on day 22 (with the option to receive vemurafenib in the extension study after completion of pharmacokinetic assessments).


Eligibility criteria:
inclusion criteria: * adult patients, 18-70 years of age * patients with either unresectable stage iiic or iv brafv600 mutation-positive metastatic melanoma or other malignant brafv600 mutation-positive tumor type and who have no acceptable standard treatment options * eastern cooperative oncology group (ecog) performance status 0 to 2 * full recovery from any major surgery or significant traumatic injury at least 14 days prior to the first dose of study treatment * adequate hematologic and end organ function * female patients of childbearing potential and male patients with female partners of childbearing potential must agree to use 2 effective methods of contraception as defined by protocol during the course of the study and for at least 6 months after completion of study treatment exclusion criteria: * prior treatment with vemurafenib or other braf inhibitor within 42 days of day 1 * prior anti-cancer therapy within 28 days (6 weeks for nitrosureas or mitocyn c, or 14 days for hormonal therapy or kinase inhibitors) before the first dose of study treatment day 1 * palliative radiotherapy within 2 weeks prior to first dose of study treatment day 1 * experimental therapy within 4 weeks prior to first dose of study treatment day 1 * history of clinically significant cardiac or pulmonary dysfunction, including current uncontrolled grade \>/=2 hypertension or unstable angina * current grade \>/=2 dyspnea or hypoxia or need for oxygen supplementation * history of myocardial infarction within 6 months prior to first dose of study treatment * active central nervous system lesions (i.e. patients with radiographically unstable, symptomatic lesions) * history of bleeding or coagulation disorders * allergy or hypersensitivity to vemurafenib or phenprocoumon formulations * history of malabsorption or other condition that would interfere with the enteral absorption of study treatment * history of clinically significant liver disease (including cirrhosis), current alcohol abuse, or active hepatitis b or hepatitis c virus infection * human immunodeficiency virus (hiv) infection requiring antiretroviral treatment, or aids-related illness * pregnant or lactating women
application of new technologies in the resection of intracranial tumors

Conditions: Intracranial Neoplasm

Summary: main outcome: to assess the effectiveness of new intraoperative technologies in the resection of intracranial tumors. design: prospective observational study. method: prospective observational study of the use and effectiveness of intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology in the resection of intracranial supratentorial tumors. number of patients: 70 - 100. duration of the study: 3 years. ethical considerations: the study will be carried out following the international ethical recommendations for medical research in humans. before beginning the study, the ethical committee of the hospital of santa creu i sant pau approved the study protocol. it is about the study of surgical techniques that we use in our usual clinical practice. fundings: there are no funding sources.


Eligibility criteria:
inclusion criteria: * intraaxial brain tumors that are tributary to surgical treatment. exclusion criteria: * extra-axial brain tumors.
topotecan and cisplatin versus etoposide and carboplatin in 1st line treatment of patients with small cell lung cancer and extensive disease (sclc-ed)

Conditions: Extensive Disease; First-Line; Small Cell Lung Cancer

Summary: randomised trial comparing standard chemotherapy with carboplatin and etoposide with a combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell type.

fase iii, multicenter randomised trial comparing up to six cycles of carboplatin and etoposide with up to six cycles of topotecan and cisplatin in patients with extensive stage small cell lung cancer and ps 0-3

Eligibility criteria:
inclusion criteria: * histologically confirmed sclc * extensive stage * no prior chemotherapy * who ps 0-3 * adequate organ function (liver, kidney) * adequate hematology (bone marrow) * informed consent exclusion criteria: * ps 4 * inadequate organ function * uncontrolled infection * concomitant major medical contraindications

Keywords: sclc extensive disease topotecan
randomized controlled trial of bipolar versus ultrasonic hemostasis techniques in thyroidectomy

Conditions: Head and Neck Cancer

Summary: rationale: the use of bipolar energy sealing system or ultrasonic coagulation for hemostasis during thyroidectomy may reduce blood loss and hypocalcemia and may be more cost-effective.

purpose: this clinical trial is studying how well bipolar energy sealing system and ultrasonic coagulation for hemostasis during thyroidectomy reduce blood loss and hypocalcemia, as well as which device is the most cost-effective approach for thyroidectomy.

Eligibility criteria:
inclusion criteria: * patients requiring thyroidectomy exclusion criteria: * patients unwilling or unable to provide informed consent * age less than 18 years old * reoperative case * patients who use pacemakers
efficacy study of sorafenib and cyclophosphamide to treat neuroendocrine tumors

Conditions: Neuroendocrine Tumors

Summary: this is a phase ii clinical trial to assess the efficacy of the combination of metronomic cyclophosphamide and tailored sorafenib dosing in advanced, progressive net. net are highly vascular tumors, and high vegf expression has been correlated with worse clinical and pathological characteristics as well as poor prognosis. a novel antiangiogenic approach relies on targeting not only the endothelial cells but also rendering them more sensitive to vegfr blockade by achieving pericyte detachment. in this study, the dose of sorafenib will be titrated up to a maximum of 800mg bid based on patients' toxicity and on a novel pharmacodynamic assay that measures inhibition of molecular target(pdgfr) in patients' peripheral blood mononuclear cells. dual vegfr targeting is achieved by administering sorafenib plus metronomic low dose cyclophosphamide.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed neuroendocrine tumors * progressive and measurable metastatic disease * patients must not have disease that is currently amenable to surgery * life expectancy of greater than 3 months * ecog performance status ≤2 * patients must have normal organ and marrow function * negative pregnancy test; agreement to use adequate birth control exclusion criteria: * patients receiving chemotherapy or radiotherapy within last 4 weeks * patients that had received sorafenib for advanced net(neuroendocrine tumors) are not allowed * any other investigational agents within 4 weeks of study * patients with known brain metastases * history of allergic reactions to compounds of similar chemical/biologic composition to sorafenib or cyclophosphamide * concurrent cancer from another primary site requiring treatment within the past 3 years * uncontrolled intercurrent illness * pregnant women and women who are breastfeeding * hiv-positive patients receiving combination anti-retroviral therapy

Keywords: neuroendocrine sorafenib cyclophosphamide pharmacodynamic